1. Home
  2. ICHR vs AUPH Comparison

ICHR vs AUPH Comparison

Compare ICHR & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ichor Holdings

ICHR

Ichor Holdings

HOLD

Current Price

$18.97

Market Cap

605.5M

Sector

Technology

ML Signal

HOLD

Logo Aurinia Pharmaceuticals Inc

AUPH

Aurinia Pharmaceuticals Inc

HOLD

Current Price

$15.87

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ICHR
AUPH
Founded
1999
1993
Country
United States
Canada
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
605.5M
1.6B
IPO Year
2016
1999

Fundamental Metrics

Financial Performance
Metric
ICHR
AUPH
Price
$18.97
$15.87
Analyst Decision
Buy
Buy
Analyst Count
5
4
Target Price
$26.50
$17.25
AVG Volume (30 Days)
548.2K
1.2M
Earning Date
02-03-2026
11-04-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.55
Revenue
$957,337,000.00
$265,808,000.00
Revenue This Year
$13.48
$21.76
Revenue Next Year
$5.55
$16.45
P/E Ratio
N/A
$29.54
Revenue Growth
16.86
20.62
52 Week Low
$13.12
$6.55
52 Week High
$35.56
$16.54

Technical Indicators

Market Signals
Indicator
ICHR
AUPH
Relative Strength Index (RSI) 60.51 54.19
Support Level $16.61 $16.00
Resistance Level $19.23 $16.54
Average True Range (ATR) 0.75 0.40
MACD 0.19 -0.06
Stochastic Oscillator 90.48 50.72

Price Performance

Historical Comparison
ICHR
AUPH

About ICHR Ichor Holdings

Ichor Holdings Ltd is engaged in the design, engineering, and manufacturing of critical fluid delivery subsystems and components for semiconductor capital equipment. The product offerings include gas and chemical delivery subsystems, collectively known as fluid delivery subsystems, which are key elements of the process tools used in the manufacturing of semiconductor devices. The company also manufactures machined components, weldments, and proprietary products for use in fluid delivery systems. Geographically, the company operates in the United States, Singapore, Europe, and Others, of which a majority of the revenue is generated from Singapore.

About AUPH Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

Share on Social Networks: